MD and CEO, Imugene
| Role | Organisation | Sources |
|---|---|---|
| MD and CEO | Imugene | @AuManufacturing, Brandon Capital portfolio |
Stories naming Leslie Chong. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Manufacturing briefs: XRF Scientific posts record results, Universal Biosensors receives an R&D tax rebate, Imugene and SMC appoint executives, FWPA promotes forestry in a new campaign, and AGL agrees a Loy Yang transition fund.
Melbourne cancer immunotherapy startup Currus Biologics, spun out of Peter MacCallum, raised $10 million led by the Brandon Capital-managed Medical Research Commercialisation Fund with Uniseed, to advance its BEAT technology toward human trials.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·Startup Daily·SmartCompany·Startup Daily